## The Take

**Consensus:** Biopharma operations tooling is solved. Enterprise vendors (Medidata, Veeva, IQVIA) serve large pharma, smaller biotechs are too fragmented and short-lived to build for, and manufacturing is a CDMO problem. Clinical trial delays are a fact of life.

**Today:** Biotech operations sits in a dual squeeze -- Veeva expanding downmarket (100+ biotechs on Basics in <2 years) and biotech mortality collapsing the customer base (first financings $2.6B to $900M in Q1-Q2 2025). Consensus sees this squeeze as proof that standalone ops tools can't survive. Actually, the squeeze is what creates the startup opportunity: 5,950 of 6,000 pharma companies still run trials on Excel, enterprise vendors structurally can't serve $0-500M biotechs (4% of Veeva revenue from emerging biotech despite years of effort), and the biotechs that survive the funding crunch need ops efficiency more than ever because every delayed trial costs $600K-$8M per day. Point solutions are proving this with 800% growth rates in the worst funding environment in 20 years.

The opportunity is a three-layer platform stack spanning the full biotech operations surface:

1. **Trial finance (top layer):** Accrual automation, budgeting, scenario modeling. 50% of clinical-stage biotechs still on Excel. Auxilius growing 800% YoY, 65+ biopharma customers. "If you are a biotech and trying to clench every cent, I would want you to use Auxilius" -- the liquidity crunch is the adoption catalyst.
2. **Clinical supply and ops (middle layer):** Supply forecasting, patient payments, trial matching. Slope at 267% YoY growth, 5,262 trials managed. Greenphire-Suvoda merged into 8-product platform serving 1,800 trials across 95 countries. $8.875B Thermo-Clario acquisition validates the category at ~7x revenue.
3. **Manufacturing intelligence (bottom layer):** Batch review, deviation detection, cross-CDMO visibility. $259B CDMO market with top 5 holding <15% share. Batch failure every 40.6 weeks at 7% rate, costing $1-2M+ per failure. GxP validation creates 18-24 month barrier to competition.

The data moat mechanism compounds across all three layers. Auxilius scenario modeling improves with each customer's data -- "more accurate because their intuitive scenario model is really based on their other customers' data." Manufacturing intelligence deepens with each batch run (deviation history, process parameters, batch genealogy). These are not features; they are institutional memory that enterprise vendors cannot replicate through acquisition alone.

The dual squeeze actually favors startups, not incumbents. Veeva's downmarket push (Basics at 100+ biotechs) focuses on regulatory and quality -- not clinical finance, supply, or manufacturing coordination. IQVIA requires $500K+ commitments and month-long implementations. Startups implement in 2-3 weeks at price points that Series A-C biotechs can afford. The <10% of SMB customers who "eventually become bigger company" create a leaky bucket dynamic -- but M&A exits ($8.875B Thermo-Clario, Greenphire-Suvoda merger) prove you don't need customers to survive forever. You need to build enough value to be acquired.

**In 3-5 years:** 2-3 platforms dominate SMB-to-midmarket biotech operations. Winners either IPO or exit at $500M-$2B+. Enterprise vendors own large pharma; platforms own Series A through mid-market. Market structure: 30% enterprise (Medidata/Veeva), 50% platforms (evolved point solutions), 20% still Excel (smallest biotechs). Manufacturing intelligence becomes standard requirement for clinical-stage biotechs. GxP-validated AI commoditizes; differentiation shifts to data moat depth and CDMO network breadth.

**How this evolved:**
- *2026-01-27:* **MERGE** -- Consolidated from five source theses: Trial Finance (Excel displacement), Biotech Ops Intelligence (point solutions become platforms), Manufacturing Intelligence (GxP moat + CDMO fragmentation), Biopharma Mfg Fragments (orchestration platform), and archived Biotech Ops $140B Market. Added dual squeeze framing and three-layer platform structure. Contrarian threats: Veeva downmarket (HIGH), biotech mortality (HIGH), AI hype correction (MEDIUM).
- *2026-01-26:* **REBUILD** (pre-merge) -- Contrarian pressure testing across all source theses. Veeva Basics faster than expected. Greenphire-Suvoda merger validated. Biotech funding showing recovery signals.
- *2025-12-29:* Original theses created from Tegus expert calls, founder interviews, M&A data.

---

## Bull Case

- [x] **50%+ of clinical-stage biotechs use no specialized tooling** -- "50% use Excel, 30% specialized, 20% big brand"; "5,950 companies still running clinical trials via Excel spreadsheets" ([[Director at a Pharmaceutical Therapeutics Company _ Greenphire _ Tegus]], [[Jake __ Virtue]])
- [x] **Point solutions achieve >100% YoY growth in downturn** -- Auxilius 800% YoY, Slope 267% YoY, 65+ biopharma customers; growth in worst biotech funding environment in 20 years = real PMF ([Auxilius Press](https://www.auxilius.co/articles/auxilius-grows-800-raises-10m-to-scale-clinical-trial-financial-management))
- [x] **M&A validates category at premium multiples** -- Thermo-Clario $8.875B (~7x revenue); Greenphire-Suvoda 8-product platform, 1,800 trials, 95 countries ([Thermo Fisher IR](https://ir.thermofisher.com/investors/news-events/news/news-details/2025/Thermo-Fisher-Scientific-to-Acquire-Clario-Holdings-Inc--Enabling-Pharma-and-Biotech-Customers-to-Accelerate-Innovation-with-Deeper-Clinical-Insights/default.aspx), [Suvoda-Greenphire](https://www.suvoda.com/insights/all-news/suvoda-and-greenphire-announce-completion-of-merger))
- [x] **Data moat compounds with each customer** -- Condor customers report 90%+ forecast accuracy improvement; Auxilius scenario modeling "based on their other customers' data" ([[Director at a Pharmaceutical Therapeutics Company _ Greenphire _ Tegus]])
- [x] **CDMO fragmentation creates structural coordination gap** -- Top 5 CDMOs hold <15% market share in $259B market; separate companies for drug substance vs. drug product, API synthesis vs. formulation ([Bourne Partners CDMO Report](https://bourne-partners.com/wp-content/uploads/2025/09/CDMO-Report-March-2025_Bourne-Partners.pdf), [Pharma's Almanac](https://www.pharmasalmanac.com/articles/what-economic-or-market-trends-are-having-the-biggest-impact-on-cdmo-capacity-and-pipelines-in-2025-and-what-will-2026-bring))
- [x] **Batch failure prevention has massive ROI** -- Failure every 40.6 weeks, 7% rate, $1-2M+ per failure; AI reduces catastrophic probability from 20-40% to ~1% ([BioProcess International](https://www.bioprocessintl.com/bioanalytical-methods/biotech-facilities-average-a-batch-failure-every-40-6-weeks), [[Sources/Granola/Virtue _ Eitri-2026-01-08_14-05-10]])
- [x] **GxP validation creates 18-24 month moat** -- FDA 21 CFR Part 11, computer system validation, ALCOA+ data integrity requirements cannot be shortcut; once validated, platform compounds value with each batch run ([[Sources/LLM-Chats/2026-01-04-eitri-2026-strategy-feedback]])
- [x] **Enterprise vendors structurally cannot serve SMB** -- Veeva emerging biotech revenue at 4% after years; suite pricing at $500K+ with month-long implementations vs. 2-3 week startup implementations ([[Vice President of Finance at Velocity Clinical Research _ Greenphire _ Tegus]])
- [ ] **AI automation accelerates Excel replacement** -- AI in clinical trials market growing 22.6% CAGR, $2B to $6.5B by 2030; 130+ GenAI use cases identified (BCC Research, [[Sources/Browser-History/2026-01-14-biopharmas-path-to-value-with-generative-ai-bcg]])
- [x] **Trial delay costs create urgency** -- 94% of trials delayed >1 month, $600K-$8M/day delay costs ([[slope-seed-pitch-deck-q4-2019]])

---

## Bear Case

- [ ] **Biotech mortality creates leaky bucket** -- First financings collapsed $2.6B to $900M Q1-Q2 2025; <10% of SMB customers "eventually become bigger company"; average customer lifetime <3 years ([Crunchbase](https://news.crunchbase.com/venture/biotech-us-funding-share-lowest-2025/), [[Director at a Pharmaceutical Therapeutics Company _ Greenphire _ Tegus]])
- [ ] **Veeva Basics expanding faster than expected** -- 100+ biotechs across 60 companies; LIMS Basics and PromoMats Basics launching 2026; AI Agents for Quality April 2026 ([Veeva](https://www.veeva.com/resources/veeva-basics-adopted-by-more-than-100-emerging-biotechs-to-simplify-and-standardize-operations/))
- [ ] **CRO bundling displaces standalone vendors** -- CROs evolving into "strategic co-developers integrating technology"; 65+ CROs accredited in Medidata ([Clinical Leader](https://www.clinicalleader.com/doc/cro-industry-outlook-the-next-stage-of-clinical-trial-transformation-0001))
- [ ] **IQVIA launches competitive clinical finance suite** -- 58% of sponsors use IQVIA; Clinical Trial Financial Suite with AI launching 2026 ([IQVIA](https://www.iqvia.com/solutions/technologies/clinical-trial-financial-suite))
- [ ] **GxP validation barrier may erode** -- Automated validation platforms (Sware, GxPNext) and FDA CSA approach reducing barrier from 18-24 months to potentially 6-12 months; "40% audit preparation time reduction" ([Sware GxPNext](https://www.sware.com/solutions/gxpnext))
- [x] **AI hype correction** -- "95% of businesses that tried AI found zero value" (MIT July 2025); manufacturing AI provides "context and signals, not answers -- human judgment remains central" ([MIT Technology Review](https://www.technologyreview.com/2025/12/15/1129174/the-great-ai-hype-correction-of-2025/))
- [ ] **Large pharma insourcing** -- AstraZeneca $2B, Merck $1.9B building internal manufacturing; reduces CDMO demand for later-stage programs ([Outsourced Pharma](https://www.outsourcedpharma.com/doc/2026-cdmo-forecast-the-shifts-sponsors-need-to-prepare-for-0001))
- [ ] **Veeva Quality Cloud captures manufacturing** -- Environmental Monitoring December 2026, Batch Release with early wins, 17/20 top pharma on CTMS ([Veeva](https://www.veeva.com/resources/veeva-ai-agents-to-be-released-across-all-veeva-applications/))

**What would have to be true for you to be wrong?** The dual squeeze would need to close completely: Veeva successfully launches clinical finance modules capturing >20% SMB market by 2028 (closing from the top), AND biotech mortality exceeds 60% through 2027 with no funding recovery (closing from the bottom). Additionally, CROs would need to successfully bundle native automation, making standalone vendors obsolete. If all three happen simultaneously, point solutions cannot achieve unit economics and the startup window shuts. The 60% VC funding recovery in back-half 2025 suggests the mortality squeeze is loosening, and Veeva's continued focus on regulatory/quality (not clinical finance) suggests the top squeeze is slower than feared. M&A exits ($8.875B Thermo-Clario) provide an alternative path even if independent scaling proves difficult.

---

## Timeline

**Now → 2026:** Window is open for point solutions. Thermo-Clario closes mid-2026. IQVIA Clinical Trial Financial Suite launches. Veeva Basics expands to LIMS and PromoMats. Entry point: Watch for Auxilius Series B, Slope strategic expansion, first GxP-validated AI manufacturing deployments. Biosecure Act creates CDMO selection urgency.

**2027 → 2028:** Consolidation wave. Winners hit $100M ARR or become acquisition targets. Expect 2-3 M&A deals at $500M-$2B. CRO bundling intensifies -- partnerships become critical. First manufacturing intelligence platform achieves 20+ clinical-stage biotech customers. Critical threshold: if Veeva Environmental Monitoring + Batch Release captures clinical biotechs (not just pharma), manufacturing intelligence thesis weakens. If biotech mortality exceeds 60%, trial ops thesis weakens.

**2029+:** 2-3 platforms dominate SMB-midmarket. Manufacturing intelligence becomes standard requirement. GxP-validated AI commoditizes; differentiation shifts to data moat depth and CDMO network breadth. Digital twins (Unlearn model) standard in Phase II/III. Excel finally dies for clinical trials. Market structure: 30% enterprise, 50% platforms, 20% Excel.

---

## Startup Opportunities

**1. Clinical Trial Finance Platform (Auxilius model) -- TOP LAYER**
- Why this follows: 50% of biotechs still on Excel for accruals; liquidity crunch makes on-time/on-budget critical; "financial management for clinical trials has been an underserved area"
- Wedge: Accrual automation for Series A-C biotechs with 2-3 week implementation; scenario modeling accuracy compounds with customer data
- Risk: Customer mortality (<10% become bigger company), Veeva downmarket expansion, customer churn as companies "grow out of" Auxilius within 5-10 years

**2. Clinical Supply and Operations Platform (Slope/Greenphire model) -- MIDDLE LAYER**
- Why this follows: 94% of trials delayed, $600K-$8M/day delay costs; real-time supply forecasting replaces 7-10 day consultant turnaround
- Wedge: API-first architecture wins CRO integrations (Slope + LabConnect); patient payments as network effect wedge (Greenphire model, "no real competitors")
- Risk: CRO bundling, late-phase dominated by CROs with own systems

**3. Manufacturing Intelligence Platform (Eitri model) -- BOTTOM LAYER**
- Why this follows: CDMO fragmentation (<15% top 5 share) creates coordination gap; 150+ hours per batch document processing; virtual biotechs lack ops capacity to navigate specialized partners
- Wedge: AI batch disposition + deviation detection with GxP validation; batch record PDF processing as entry point; $50K-$100K+ ACV per clinical program
- Risk: Veeva Quality Cloud expansion (Environmental Monitoring December 2026), Apprentice.io batch review capabilities, biotech consolidation compresses TAM

**4. Digital Twins for Control Arms (Unlearn model) -- CROSS-CUTTING**
- Why this follows: EMA qualified, FDA aligned; 25-50% enrollment reduction potential; PROCOVA method reduces variance 10-20%
- Wedge: 280 patients saved in Phase III; AI infrastructure layer required to operationalize
- Risk: Regulatory uncertainty in new indications beyond CNS

---

## Watch For

**If RIGHT:** Auxilius or Condor announces Series B or acquisition at >$300M by Q4 2026. Another point solution M&A at $500M+. Manufacturing intelligence platform achieves 20+ clinical biotech customers. Major CDMO partnership validates industry acceptance (Lonza, Samsung Biologics). Batch failure rates decline measurably for platform users (7% to <3%). AI in clinical trials adoption exceeds 50% of Phase I/II trials by 2028.

**If WRONG:** Biotech mortality exceeds 60% through 2027; point solution growth stalls below 50% YoY. Veeva launches clinical finance module capturing >20% SMB market by 2028. CROs bundle native automation; standalone vendors obsolete. IQVIA Clinical Trial Financial Suite captures majority of clinical-stage biotechs. Veeva announces manufacturing intelligence product capturing clinical-stage biotechs. AI hype correction deepens -- manufacturing AI fails to deliver ROI. Microsoft Copilot/AI makes Excel adequate for forecasting.

---

## Evidence

| Date | Source | Type | Key Signal |
|------|--------|------|------------|
| 2025-12 | [[Jake __ Virtue]] | Founder | "5,950 companies still running clinical trials via Excel spreadsheets; only 50 of 6,000 do forecasting" |
| 2025-12 | [[Sources/Granola/Granola 1/Quinn Johns and Virtue]] | Founder | "Virtual biotechs (10-person teams) struggle to navigate constellation of manufacturing partners; CDMO fragmentation increasing" |
| 2025-12 | [[Sources/Granola/Quinn Johns and Virtue-2025-12-15_14-00-38]] | Founder | "Drug complexity drives specialization; target CTOOs at innovative clinical biopharma" |
| 2025-07 | [[Director at a Pharmaceutical Therapeutics Company _ Greenphire _ Tegus]] | Operator | "50/30/20 market split; Auxilius 10X growth; <10% become bigger company; scenario modeling from customer data" |
| 2025-07 | [[Vice President of Finance at Velocity Clinical Research _ Greenphire _ Tegus]] | Operator | "If you are a biotech and trying to clench every cent, I would want you to use Auxilius; sweet spot pre-clinical to $500M" |
| 2025-10 | [Thermo Fisher IR](https://ir.thermofisher.com/investors/news-events/news/news-details/2025/Thermo-Fisher-Scientific-to-Acquire-Clario-Holdings-Inc--Enabling-Pharma-and-Biotech-Customers-to-Accelerate-Innovation-with-Deeper-Clinical-Insights/default.aspx) | M&A | "Thermo Fisher acquires Clario for $8.875B + $400M earnout; ~7x revenue; closing mid-2026" |
| 2025-04 | [Suvoda-Greenphire](https://www.suvoda.com/insights/all-news/suvoda-and-greenphire-announce-completion-of-merger) | M&A | "Merger completed Q2 2025; 8-product platform; 1,800 trials, 95 countries, 1M+ participants" |
| 2026-01 | [[Sources/Granola/Virtue _ Eitri-2026-01-08_14-05-10]] | Founder | "Batch failure 20-40% to 1%, 150+ hours processing per batch, $5-10M per failure avoided" |
| 2026-01 | [[Sources/Granola/Virtue _ Eitri-2026-01-08_12-59-12]] | Founder | "Batch failures cause 6-9 month delays, $5-10M spend; biotech-CDMO collaboration high friction" |
| 2026-01 | [[Sources/LLM-Chats/2026-01-04-eitri-2026-strategy-feedback]] | Research | "GxP validation as 18-24 month moat; Veeva Batch Release MEDIUM threat; tech transfer 8+ months" |
| 2026-01 | [[Sources/LLM-Chats/2026-01-02-ai-biomanufacturing-wedge-analysis]] | Research | "Aizon 3.5% yield; Katalyze 5-8% productivity; 70% biomanufacturing data unused; 5% batch failure rate" |
| 2026-01 | [[Sources/LLM-Chats/2026-01-13-biofit-comprehensive-report]] | Research | "$155B CDMO market @ 7.4% CAGR; CGT manufacturing $32B to $403B @ 28.8% CAGR" |
| 2026-01 | [[Sources/Browser-History/2026-01-14-biopharmas-path-to-value-with-generative-ai-bcg]] | Research | "130+ GenAI use cases; 30% productivity gains in quality management, clinical development" |
| 2026-01 | [[Sources/Granola/ChipperBot __ Virtue-2026-01-23_13-30-10]] | Founder | "LLMs enable reading instrument logs; pilots at Grail, JGI; industry has software budgets but no ops data platform" |
| 2026-01 | [[Milind __ Virtue]] | Founder | "New specialized manufacturing facilities being built as redundancy nodes; Lonza and generic manufacturers expressing strong interest" |
| 2026-01 | [[katalyze-291b8fac]] | Company | "Katalyze Yield Agent: Sanofi 5-8% productivity increase, $8M average saving per site" |
| 2026-01 | [[tegus_aizon_01HV1FYT1RD9YRJZSGWBXAHR50_Customer-of-Aizon]] | Operator | "3.5% yield improvement on $10,000/gram molecule = millions in profit" |
| 2026-01 | [[tegus_aizon_34946_former-head-of-product-at-servicenow-c4c04bac]] | Operator | "Unified data architecture definitely required for manufacturing agility" |
| 2026-01 | [[tegus_sartorius-ag_82226_director-vaccine-manufacturing-comm-dbdce7b1]] | Operator | "Leaders at different sites willing to look at anything if it can streamline things" |
| 2025-12 | [[slope-seed-pitch-deck-q4-2019]] | Company | "94% of trials delayed >1 month, $600K-$8M/day delay costs" |
| 2025-12 | [[slope-series-a-pitch-deck_from_deals-a6027cad]] | Company | "Slope 267% YoY growth, 5,262 trials managed, 581 global research sites" |
| 2025-12 | [[unlearnai_pitch-1-1-18540aa6]] | Company | "Digital twins 50% cost reduction; FDA supports use in clinical trials" |
| 2025-12 | [[2025-12-23-ai-agents-are-rewriting-biopharmas-140b-playbook--]] | Research | "$140B outsourcing market; CROs projected $70B to $126B by 2034; $350B AI value potential" |
| 2025-01 | [[Contract Process Operations Lead, J&J Innovative Medicine at The Janssen Pharmaceutical Companies of Johnson & Johnson _ Greenphire _ Tegus]] | Operator | "Greenphire 'no real competitors' in patient payments" |
| 2025-12 | [[alchemi-05811b92]] | Company | "Report writing consumes 20-30% of scientist time; ~$30B/year in lost productivity" |
| 2025-12 | [[Sources/Market-Research-PDFs/digitalization-of-biomanufacturing_-a-status-update-2f15e485]] | Research | "Only ~10% of generated manufacturing data actually used; batch digitalization still rare" |
| 2025-12 | [[Sources/Research-Papers/Automation in Clinical Trial Statistical Programming A Structured Review of TLF Generation, Validati]] | Research | "87.8% manual TLF programming; 78.1% require >6 hours per table" |
| 2026-01 | Web: BioProcess International | Research | "Batch failure every 40.6 weeks; 7% failure rate; costs >$1-2M per failure" |
| 2026-01 | Web: Pharma's Almanac CDMO | Research | "Top 5 CDMOs <15% market share; $200B market in 2025" |
| 2026-01 | Web: Veeva Announcements | Competitor | "Environmental Monitoring Dec 2026; AI Agents for Quality April 2026; Batch Release early wins" |
| 2026-01 | Web: MIT Technology Review | Contrarian | "95% of businesses found zero AI value; great AI hype correction of 2025" |
| 2026-01 | Web: Crunchbase | Market | "Biotech share of US VC at historic low; first financings $2.6B to $900M Q1-Q2 2025" |
| 2026-01 | Web: Outsourced Pharma | Research | "AstraZeneca $2B, Merck $1.9B building internal manufacturing; large pharma insourcing" |
| 2025-11 | [[As pharmas pour billions in US manufacturing, CDMOs see future opportunities]] | News | "$480B+ pharma US manufacturing pledged since early 2025; Recipharm CEO: '75% will be for sale in 10 years'; 80% of FDA-approved drugs from smaller companies relying on CDMOs; BMS sold facility to Rovi, Sanofi to Thermo Fisher" |
| 2025-07 | [[2025-12-23-the-state-of-the-emerging-biotech-market-bio]] | News | "BIO report: biotech funding $2.6B Q1 2025 to $900M Q2 2025 (65% decline); IPOs from 40/yr pre-COVID to 15 in 2023; 65 layoffs Q1 2025 alone — validates biotech mortality squeeze" |
| 2023-06 | [[series-a-crunch-prepare-for-new-world-order-fdd594ac]] | Research | "VC capital supply reduced 40-75%; seed-to-Series A graduation expected to drop from 32-40% to 20-30%; Series A step-ups compressed from 5-20x to 2-3x; two healthcare seed firms wound down" |
| 2023-08 | [[VEEV-2024-Q2]] | Operator | "Veeva <20% penetrated in R&D; emerging biotech macro softness confirms dual squeeze — 4% emerging biotech revenue despite years of effort proves structural SMB underservice" |
| 2025-01 | [[resonata-v0992-full]] | Research | "85% of trials delayed by accrual; $6,533 avg cost per patient enrolled; $19,533 per dropped patient; $600K-$8M/day delay costs; 17-yr treatment adoption cycle" |
| 2022-11 | [[202211-gc-hc-platform-benchmarking]] | Research | "HC software: 40% EBITDA, 28% FCF margins (70% conversion) vs services: 20% EBITDA, 9% FCF; software commands ~3x revenue premium; ~3 years of 100%+ growth for HC platform companies" |
| 2025-08 | [[Virtue VC & FCA VP Catch-up]] | Operator | "E Tree AI building electronic batch record review (pre-seed, Atria Adventures); Standard Model Bio multimodal foundation models for pharma; Solstice $3M round at $12.5M post" |
| 2023-12 | [[VEEV-2024-Q3]] | Operator | "Gassner: 'small biotechs who can't get funding don't start up'; clinical products require extreme conservatism: 'nobody is yet using our RTSM for all studies' — confirms dual squeeze and conservative adoption" |
| 2026-01 | [[2026-01-07-deffai]] | News | "Deffai: AI-native regulatory strategy platform for lean biotech teams covering Regulatory, CMC, Tech Ops, Process Validation — confirms 5,950 of 6,000 pharma companies need ops tooling" |

---

*Confidence: MEDIUM-HIGH -- Dual squeeze (Veeva downmarket + biotech mortality) is real but manageable through M&A exits and funding recovery signals. Three independent validation pillars: (1) operator testimony from Tegus expert calls confirming 50% Excel status quo, (2) M&A validation at $8.875B Thermo-Clario, (3) growth metrics (800% YoY) in worst funding environment. Manufacturing layer is MEDIUM confidence (GxP moat faces Veeva Quality Cloud threat). Trial ops layer is HIGH confidence (M&A proven, growth proven). The key risk is whether point solutions can achieve unit economics with <3 year average customer lifetime and <10% graduation rate.*
*Last rebuilt: 2026-01-27*
